The short version
Only one company currently supplies this market — there is no backup if it stumbles.
Market view
lopinavir and ritonavir · Solution
1 marketed package NDCs · 1 active manufacturer
Most dispensed: 200 mg; 50 mg · Tablet, Film Coated · #120 tablet, film coateds/bottle · 100 mg; 25 mg · Tablet, Film Coated · #60 tablet, film coateds/bottle
What changed in the last 90 days
Every detected change for lopinavir and ritonavir, newest first — price moves, shortages, recalls, and manufacturers entering or leaving. Detected by comparing each day’s federal data against the day before.
- Lopinavir and RitonavirSep 2, 2026Mfr exitedAbbVie Deutschland GmbH & Co Kg · lopinavir and ritonavir
- Lopinavir and RitonavirAug 20, 2026Mfr enteredAbbVie Deutschland GmbH & Co Kg · lopinavir and ritonavir
- Lopinavir and RitonavirAug 19, 2026Price upNADAC $4.42175 → $4.44338 per unit (+0.49%)
- Lopinavir and ritonavirAug 19, 2026Price upNADAC $4.42175 → $4.44338 per unit (+0.49%)
- Lopinavir and RitonavirJul 29, 2026Mfr exitedAbbVie Deutschland GmbH & Co Kg · lopinavir and ritonavir
- KaletraJul 25, 2026New shortageby this manufacturerAbbVie Inc.'s Kaletra (Tablet, 100 mg; 25 mg) is newly in shortage5 companies market kaletra
- KaletraJul 25, 2026New shortageby this manufacturerAbbVie Inc.'s Kaletra (Tablet, 100 mg; 25 mg) is newly in shortage5 companies market kaletra
- KaletraJul 25, 2026New shortageby this manufacturerAbbVie Inc.'s Kaletra (Oral Solution, 80 mg/1 mL; 20 mg/1 mL) is newly in shortage5 companies market kaletra
- KaletraJul 25, 2026New shortageby this manufacturerAbbVie Inc.'s Kaletra (Tablet, 200 mg; 50 mg) is newly in shortage5 companies market kaletra
- KaletraJul 25, 2026New shortageby this manufacturerAbbVie Inc.'s Kaletra (Tablet, 200 mg; 50 mg) is newly in shortage5 companies market kaletra
Same drug class
Other molecules FDA puts in Cytochrome P450 3A Inhibitor, with whether each is in shortage right now. Same class is not the same drug — substitution is a clinical decision, and this is a supply picture, not a recommendation.
- atazanavir and cobicistat· 1 maker
- elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide· 1 maker
- ritonavir 100 mg· 1 maker
- darunavir, cobicistat, emtricitabine, and tenofovir alafenamide· 2 makers
- elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate· 2 makers
- darunavir ethanolate and cobicistat· 3 makers
- cobicistat· 4 makers
- ritonavir· 14 makers
Common questions
- Is Lopinavir and ritonavir in shortage right now?
- No. FDA does not currently list Lopinavir and ritonavir in shortage. This page is rebuilt every morning from FDA's shortage database, so a new posting appears here the day it is published.
- Who makes Lopinavir and ritonavir?
- 5 companies have marketed Lopinavir and ritonavir in the last 30 days, according to the FDA NDC Directory. Every manufacturer and package is listed on this page.
- What does Lopinavir and ritonavir cost?
- The typical pharmacy pays about $4.44 per unit, based on the most recent CMS NADAC survey of actual acquisition costs. That is what the pharmacy pays for the drug itself — not the cash price, and not what an insurer is billed.
Shortage reports for this molecule
- Planned discontinuation — Kaletra, Oral Solution, 80 mg/1 mL; 20 mg/1 mL (NDC 0074-3956-46)Jul 24, 2026
All marketed products
Expand a strength to see its dosage forms, then package sizes, then each manufacturer and NDC. Click an NDC for its full detail page.